Analysts predict that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will post $5.32 earnings per share for the current quarter, according to Zacks. Six analysts have provided estimates for Regeneron Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $4.55 and the highest estimate coming in at $5.73. Regeneron Pharmaceuticals posted earnings per share of $5.45 during the same quarter last year, which indicates a negative year-over-year growth rate of 2.4%. The firm is expected to announce its next earnings results on Thursday, August 1st.
According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full year earnings of $21.85 per share for the current financial year, with EPS estimates ranging from $18.82 to $23.30. For the next fiscal year, analysts expect that the firm will report earnings of $24.98 per share, with EPS estimates ranging from $20.49 to $28.75. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share for the quarter, missing the consensus estimate of $5.24 by ($0.79). The company had revenue of $1.71 billion during the quarter, compared to analyst estimates of $1.76 billion. Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. The company’s revenue was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.67 EPS.
Several brokerages have recently commented on REGN. Canaccord Genuity reiterated a “hold” rating and set a $353.00 price target (down previously from $408.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, May 8th. BMO Capital Markets lowered their price target on shares of Regeneron Pharmaceuticals from $412.00 to $375.00 and set a “market perform” rating for the company in a research report on Wednesday, May 8th. Cantor Fitzgerald lowered their price target on shares of Regeneron Pharmaceuticals from $441.00 to $405.00 and set a “neutral” rating for the company in a research report on Monday. UBS Group lowered their price target on shares of Regeneron Pharmaceuticals from $480.00 to $440.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Finally, Morgan Stanley lowered their price target on shares of Regeneron Pharmaceuticals from $420.00 to $389.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 8th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $404.88.
In related news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total transaction of $305,930.00. Following the transaction, the director now owns 11,323 shares of the company’s stock, valued at approximately $3,464,045.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Sanofi sold 131,115 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $412.17, for a total transaction of $54,041,669.55. The disclosure for this sale can be found here. Insiders have sold a total of 141,968 shares of company stock worth $57,360,056 in the last three months. 11.84% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Smithfield Trust Co. bought a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $27,000. Whittier Trust Co. boosted its stake in Regeneron Pharmaceuticals by 195.7% during the 4th quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 45 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $29,000. Citizens Financial Group Inc RI bought a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $30,000. Finally, AdvisorNet Financial Inc boosted its stake in Regeneron Pharmaceuticals by 208.0% during the 4th quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 52 shares during the last quarter. 67.63% of the stock is currently owned by institutional investors and hedge funds.
REGN traded up $2.50 during midday trading on Friday, hitting $307.12. The company had a trading volume of 735,828 shares, compared to its average volume of 782,783. The company has a current ratio of 4.58, a quick ratio of 3.78 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $33.82 billion, a PE ratio of 15.51, a PEG ratio of 1.44 and a beta of 1.08. Regeneron Pharmaceuticals has a twelve month low of $291.10 and a twelve month high of $442.00.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Recommended Story: What is the Book Value of a Share?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.